Elemental Machines, a manufacturer of universal laboratory asset management technology for research, clinical, and testing labs around the world, announced its successful acquisition of the Tetra Lab Monitoring business from Boston-based TetraScience. The acquisition comes on the heels of a landmark year for Elemental Machines, which recently unveiled groundbreaking asset scheduling and utilization monitoring solutions, and nearly doubled the number of labs served by its universal LabOps platform.

Purchase of key TetraScience Lab Monitoring business hardware, talent, and novel asset integrations creates a clear leader in the eBy bringing Tetra Lab Monitoring under the Elemental Machines roof, we’re doubling down on our commitment to the acceleration of science. The addition of the Tetra Lab Monitoring team and technology will be invaluable as we continue our growth in service of the LabOps community.merging field of LabOps.

— Sridhar Iyengar, Elemental Machines CEO

For more, see the Elemental Machines press release.

Agrivida, a privately held biotechnology company, announces the deregulation of its innovative GRAINZYME® Phytase enzyme feed additive by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA’s APHIS). Deregulation is effective as of September 21, 2021.

Tiba Biotech announces the funding of an mRNA-based universal influenza vaccine project with support from the National Institute of Allergy and Infectious Diseases (NIAID) and its Collaborative Influenza Vaccine Innovation Centers (CIVIC) initiative. This moves forward Tiba’s earlier universal influenza collaboration with Prof. Florian Krammer of the Icahn School of Medicine at Mount Sinai.

For more, see the Tiba news post.

Revela completed the final phase of an NIH contract for the non-invasive detection of human CD8+ T cells: A PET-based approach to assess the human immune system. Current methods to predict responses to immunotherapy are inadequate. Revela has shown that tracking the short-term infiltration of CD8+ T cells into a tumor can predict longer-term responses to immunotherapy, and therefore has the potential to help clinicians more accurately tailor treatment plans. The overall goal of this contract was the successful preclinical development of a product for in vivo tracking of intratumoral human CD8+ T cells using PET imaging. A panel of novel VHHs targeting human CD8 protein have been developed and are entering late-stage preclinical development over the coming year..

For more, see the Revela website.

Tiba Biotech was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health.  In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.

The proposal is to develop an RNA-based multi-antigen SARS-CoV-2 vaccine, supporting NIAID’s call to develop a vaccine using emerging antigen design strategies and novel delivery approaches. The SARS-CoV-2 pandemic is actively threatening public health, world economies, and ways of life. Vaccine candidates are in human trials now, but long-term solutions will require an adaptable vaccine system that can be universalized broadly to all members of the coronavirus family.

For more, see the Tiba news post.